<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="362651">
  <stage>Registered</stage>
  <submitdate>18/06/2012</submitdate>
  <approvaldate>19/06/2012</approvaldate>
  <actrnumber>ACTRN12612000656831</actrnumber>
  <trial_identification>
    <studytitle>Breast-milk and infant nutrition study</studytitle>
    <scientifictitle>An observational, cross-sectional study on the effect of maternal blood folic acid and total folate status on human milk folate-binding protein concentration and infant folate status at 8 weeks postpartum.</scientifictitle>
    <utrn>U1111-1131-9116</utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Folic acid status</healthcondition>
    <healthcondition>Total folate status</healthcondition>
    <healthcondition>Human milk folate concentration</healthcondition>
    <healthcondition>Other nutritional indices (vitamins B6 and B12, choline, betaine, dimethylglycine, methioinine, homocysteine, cysteine, cystathionine, iron, zinc, and selenium)</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Breast feeding</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The primary exposure of interest is the blood folic acid concentration and blood folate status of the mother. The study aims to observe the effect of maternal blood folate status on milk folate-binding protein concentration and on infant blood folate status. Blood folic acid status and blood total folate status of the mother are assessed at 8 weeks postpartum (the folate status of the mother will be conditional on the previous folate and folic acid intake, most likely over the course of the pregnancy as steady state concentrations are only reached after 40 or more weeks). Folate-binding protein concentration and total folate in breast-milk at 8 weeks postpartum is also measured as an exposure variable in relation to infant folate status.</interventions>
    <comparator>NA</comparator>
    <control>Uncontrolled</control>
    <interventioncode>Not applicable</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Human milk folate-binding protein concentration assessed by ELISA assay</outcome>
      <timepoint>8 weeks postpartum</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Infant total serum folate status assessed by isotope dilution-liquid chromatography-tandem mass spectrometry</outcome>
      <timepoint>8 weeks postpartum</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Infant total whole-blood folate status assessed by isotope dilution-liquid chromatography-tandem mass spectrometry</outcome>
      <timepoint>8 weeks postpartum</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Blood one-carbon metabolites of the mother and infant assessed by isotope dilution-liquid chromatography-tandem mass spectrometry methods</outcome>
      <timepoint>8 weeks postpartum</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Maternal age 18 to 42 years
Healthy singleton infant born between 37 to 42 weeks gestation inclusive
Exclusive breastfeeding</inclusivecriteria>
    <inclusiveminage>7</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>9</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>High risk pregnancy (eclampsia or HELLP syndrome)
Diabetes
Cardiac disease
Renal disease
Inflammatory bowel syndrome
Coeliac Disease
Gastric bypass surgery
Medications (valproic acid, carbamazepine, phenobarbital, primidone, methotrexate, fluorouracil, premetrexed, pyrimethamine, trimethoprim, thiazide diuretics, sulfasalazine, pancreatin, cholestryramine, colestipol, metformin)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration>Cross-sectional</duration>
    <selection>Convenience sample</selection>
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>7/08/2012</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>70</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Dunedin</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Lisa Houghton</primarysponsorname>
    <primarysponsoraddress>Department of Human Nutrition
University of Otago
PO Box 56 
Dunedin 9054</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Otago Research Grant</fundingname>
      <fundingaddress>Research and Enterprise Office
Centre for Innovation
University of Otago
PO Box 56 
Dunedin 9054</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to measure the amount of folate-binding protein in human milk and to determine if it is down-regulated by high folic acid consumption using maternal blood folic acid and total folate status as biomarkers.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>University of Otago Human Ethics Committee</ethicname>
      <ethicaddress>PO Box 56
University of Otago
Dunedin 9054</ethicaddress>
      <ethicapprovaldate>20/04/2012</ethicapprovaldate>
      <hrec>1/12/0086</hrec>
      <ethicsubmitdate>5/04/2012</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Lisa Houghton</name>
      <address>Human Nutrition Department
PO Box 56
University of Otago
Dunedin 9054</address>
      <phone>+64,3,4797294</phone>
      <fax />
      <email>lisa.houghton@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rosemary Stamm</name>
      <address>Human Nutrition Department
PO Box 56
University of Otago
Dunedin 9054</address>
      <phone>+64,3,4797948</phone>
      <fax />
      <email>rosemary.stamm@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Rosemary Stamm</name>
      <address>Human Nutrition Department
PO Box 56
University of Otago
Dunedin 9054</address>
      <phone />
      <fax />
      <email>rosemary.stamm@otago.ac.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>